9 years of historical data (2017–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Vir Biotechnology, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $835M | $1.0B | $1.3B | $3.4B | $5.6B | $3.2B | $1.4B | — | — |
| Enterprise Value | $1.2B | $788M | $875M | $1.2B | $2.7B | $5.4B | $2.8B | $1.2B | — | — |
| P/E Ratio → | -2.88 | — | — | — | 6.61 | 10.57 | — | — | — | — |
| P/S Ratio | 18.49 | 12.18 | 13.48 | 15.66 | 2.11 | 5.10 | 47.45 | 1904.67 | — | — |
| P/B Ratio | 1.65 | 1.09 | 0.87 | 0.85 | 1.64 | 3.90 | 4.45 | 3.19 | — | — |
| P/FCF | — | — | — | — | 2.14 | — | — | — | — | — |
| P/OCF | — | — | — | — | 2.05 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 11.50 | 11.79 | 14.30 | 1.67 | 4.91 | 42.01 | 1751.23 | — | — |
| EV / EBITDA | — | — | — | — | 3.20 | 12.60 | — | — | — | — |
| EV / EBIT | — | — | — | — | 3.23 | 12.78 | — | — | — | — |
| EV / FCF | — | — | — | — | 1.69 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Vir Biotechnology, Inc. earns an operating margin of -682.7%. Operating margins have expanded from -794.0% to -682.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -45.7% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.9% | 82.9% | -545.0% | -564.7% | 61.6% | 53.1% | 100.0% | 100.0% | -11447.1% | -41854.4% |
| Operating Margin | -682.7% | -682.7% | -791.3% | -794.0% | 51.6% | 38.4% | -441.6% | -25032.2% | -13674.2% | -54696.0% |
| Net Profit Margin | -638.9% | -638.9% | -703.4% | -713.7% | 31.9% | 48.3% | -444.1% | -24568.6% | -13350.7% | -46880.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.7% | -45.7% | -38.1% | -33.5% | 29.4% | 49.2% | -52.4% | -142.7% | — | — |
| ROA | -36.5% | -36.5% | -31.5% | -26.1% | 21.7% | 36.8% | -41.7% | -49.6% | -52.3% | -27.8% |
| ROIC | -40.3% | -40.3% | -35.3% | -36.3% | 48.5% | 40.1% | -67.0% | -271.8% | — | — |
| ROCE | -42.8% | -42.8% | -38.8% | -33.9% | 42.7% | 34.6% | -46.7% | -58.9% | -60.7% | -34.1% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $234M exceeds total debt of $187M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.24 | 0.09 | 0.08 | 0.06 | 0.10 | 0.10 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | 0.15 | 0.32 | — | — | — | — |
| Net Debt / Equity | — | -0.06 | -0.11 | -0.07 | -0.35 | -0.15 | -0.51 | -0.26 | — | — |
| Net Debt / EBITDA | — | — | — | — | -0.86 | -0.49 | — | — | — | — |
| Debt / FCF | — | — | — | — | -0.45 | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($234M) exceeds total debt ($187M)
Short-term solvency ratios and asset-utilisation metrics
Vir Biotechnology, Inc.'s current ratio of 5.54x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 9.05x to 5.54x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.54 | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 | 7.80 | 6.81 | 2.95 | 15.46 |
| Quick Ratio | 5.54 | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 | 7.80 | 6.81 | 2.95 | 15.46 |
| Cash Ratio | 4.99 | 4.99 | 7.57 | 8.68 | 4.70 | 2.08 | 7.44 | 6.48 | 2.47 | 15.11 |
| Asset Turnover | — | 0.07 | 0.05 | 0.04 | 0.58 | 0.56 | 0.07 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 19.17 | — | — | — | 257.60 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Vir Biotechnology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 15.1% | 9.5% | — | — | — | — |
| FCF Yield | — | — | — | — | 46.8% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $139M | $136M | $134M | $135M | $133M | $119M | $108M | $97M | $7M |
Compare VIR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| VIRYou | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| CRMD | $559M | -23.8 | — | — | 92.7% | -51.4% | -23.2% | -46.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 9 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how VIR stacks up against sector leader BioNTech SE.
Start ComparisonVir Biotechnology, Inc.'s current P/E ratio is -2.9x. The historical average is 8.6x.
Vir Biotechnology, Inc.'s return on equity (ROE) is -45.7%. The historical average is -33.4%.
Based on historical data, Vir Biotechnology, Inc. is trading at a P/E of -2.9x. Compare with industry peers and growth rates for a complete picture.
Vir Biotechnology, Inc. has 82.9% gross margin and -682.7% operating margin.